Phase I/Ib Trial Evaluating the Safety and Efficacy of BET Inhibitor, ZEN003694 With PD-1 Inhibitor, Nivolumab With or Without CTLA-4 Inhibitor, Ipilimumab in Solid Tumors
Latest Information Update: 05 Jun 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; ZEN 3694 (Primary)
- Indications Carcinoma; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- 14 Dec 2023 Planned End Date changed from 1 Jan 2024 to 1 Jan 2026.
- 14 Dec 2023 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2026.
- 06 Dec 2022 Planned End Date changed from 1 Jan 2023 to 1 Jan 2024.